Followers | 2 |
Posts | 34 |
Boards Moderated | 0 |
Alias Born | 06/06/2017 |
Monday, June 19, 2017 8:11:14 AM
https://www.twst.com/interview/interview-with-the-chairman-and-ceo-isoray-inc-nysemkt
Good intell in there:
TWST: In fiscal year 2016, you had $4.7 million in revenue, with close to 90% of that related to prostate cancer treatment. How quickly do you see some of this revenue diverting to some of these new applications?
Mr. LaVoy: The new applications have been a growing percentage of IsoRay’s business over the past five years. The prostate treatment market represented over 95% of our business five years ago, and over the last two years we have reported that other applications have grown to approximately 12% of IsoRay’s sales. One of the key factors for the surgical applications has been that there has been no reimbursement in place as of yet for these applications. In late 2016, IsoRay collaborated with GammaTile and submitted an application for reimbursement to Medicare for radiation treatment of the brain at the time of surgery. The company also filed for FDA clearance for the device in March 2017.
The GammaTile product was developed by a group of doctors at the highly respected Barrow Neurological Institute. They took a collagen matrix that was developed for brain surgery and inserted our Cesium-131 seeds. In the past radiation was always done after surgery, but with the Cesium-131 application it is performed at the time of surgery. The recurrent brain tumor market is estimated to be approximately 50,000 to 70,000 patients a year. If the reimbursement codes and 510 K clearance is obtained this summer, we will have a new product that could be introduced into the market with significant growth potential over the next one to three years.
TWST: Are you currently selling internationally?
Recent CATX News
- Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024 • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- Perspective Therapeutics to Participate in Upcoming Investor Conferences in September • GlobeNewswire Inc. • 08/28/2024 11:00:00 AM
- Rumble Shares Up 7% in Premarket After 27% Q2 Revenue Surge; More on Earnings • IH Market News • 08/13/2024 09:39:29 AM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results • GlobeNewswire Inc. • 08/12/2024 08:05:59 PM
- U.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices Climb • IH Market News • 08/12/2024 09:47:41 AM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences in August • GlobeNewswire Inc. • 07/30/2024 11:00:00 AM
- Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/22/2024 11:00:00 AM
- Perspective Therapeutics Announces Inclusion in the Russell 3000® Index • GlobeNewswire Inc. • 06/12/2024 11:00:00 AM
- Perspective Therapeutics Announces 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 06/11/2024 11:00:00 AM
- Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting • GlobeNewswire Inc. • 06/10/2024 08:10:00 PM
- Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 05/24/2024 12:01:41 PM
- Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 • GlobeNewswire Inc. • 05/20/2024 11:00:03 AM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Perspective Therapeutics Announces $87.4 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 02:45:00 PM
- Perspective Therapeutics to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM